AngioDynamics: The NanoKnife Reimbursement Wave Finally Breaks
Record prostate procedure volumes and the Palmetto LCD push Med Tech growth above 18% even as tariffs bite
ANGO · Earnings Call · 2026-07-14
The Reimbursement Catalyst Arrives
Jim Clemmer opened the call with a clear victory lap: “We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year Med Tech growth of more than 18% tells the story.” — Jim Clemmer, Chief Executive Officer · 2026-07-14 That growth is now being powered by the long-awaited reimbursement tailwind for NanoKnife. The CPT I code went live in January, and during the quarter the company received a positive Medicare coverage decision from Palmetto — a first for the platform. CFO Steve Trowbridge described it as “an important decision for us” — Steve Trowbridge, Executive Vice President and Chief Financial Officer · 2026-07-14 and noted the early adoption anecdotes are already showing up: “We hit record procedure volumes during the quarter.” — Steve Trowbridge, Executive Vice President and Chief Financial Officer · 2026-07-14 That reimbursement progress is exactly what management had flagged as the key variable a year ago. On the July 2025 call, Trowbridge had warned: “It may not be immediate. It's not like a light switch.” — Steve Trowbridge, Executive Vice President and Chief Financial Officer · 2025-07-15 The FY2026 Q4 results suggest the light is finally flickering on. The Palmetto LCD, combined with a category-1 code, is driving urologist adoption and a step-change in probe sales — disposables grew 47% in the quarter. And the company is already looking beyond prostate: CEO Jim Clemmer notes the clinical data engine is expanding into BPH, a market he says "dwarfs the prostate market" — “We're hearing these anecdotes in the field, it really inspired us to do this.” — Jim Clemmer, Chief Executive Officer · 2026-07-14Growth with Cash Discipline
The bigger picture is the successful transformation of AngioDynamics from a slow growth med-device name into a higher-growth Med Tech compounder. Med Tech is now 47% of revenue, up from roughly 22% at the end of fiscal 2020, with a six-year CAGR of approximately 24%. Mechanical Thrombectomy grew 13.4% for the year, and Auryon delivered its 20th consecutive quarter of double-digit growth. This mix shift is doing exactly what it should for margins — gross margin expanded 130bp year-over-year in Q4 — but the real highlight is cash generation. Despite absorbing $4.8 million in tariffs (a line item that didn't exist a year ago) and building inventory ahead of the sterilization vendor shutdowns, the company still generated $3.1 million of operating cash flow for the year. Trowbridge underlined the achievement:That cash generation is not an accident — it's the product of a deliberate strategy that pairs a steady med-device annuity with high-growth platforms. The balance sheet remains debt-free, with $53.9 million in cash and net cash of roughly $76M at last filing. Combined with still-negative but improving free cash flow, this gives the company ample room to fund the clinical pipeline (APEX-Return, PAVE, AMBITION BTK, and the new RELIEF study) without diluting shareholders.The fact that we still generated cash from operations for the year while absorbing all of that really speaks to the underlying cash generation profile of our business model.